| 自体周血干细胞移植治疗多发性骨髓瘤研究进展 |
| |
| 引用本文： | 黄金波.自体周血干细胞移植治疗多发性骨髓瘤研究进展[J].中国慢性病预防与控制,2011,19(3):311-313. |
| |
| 作者姓名： | 黄金波 |
| |
| 作者单位： | 中国医学科学院北京协和医学院血液学研究所血液病医院,天津,300030 |
| |
| 摘 要： | 与传统化疗相比，自体干细胞移植患者完全缓解（CR）、非常好的部分缓解（VGPR）、无进展生存期及总生存期均明显提高，已成为65岁以下初治多发性骨髓瘤患者一线治疗。新药沙利度胺、来那度胺和硼替佐米联合地塞米松用于移植前的诱导化疗、预处理和维持治疗，显示出良好疗效，已逐步取代传统化疗方案，在复发和进展患者中亦显示出明显的疗效。初步研究提示来那度胺和硼替佐米可克服不利遗传学异常影响。
|
| 关 键 词： | 多发性骨髓瘤 自体干细胞移植 沙利度胺 来那度胺 硼替佐米 |
The Progress of Autologous Stem Cell Transplantation for Multiple Myeloma |
| |
| Huang Jin-bo.The Progress of Autologous Stem Cell Transplantation for Multiple Myeloma[J].Chinese Journal of Prevention and Control of Chronic Non-Communicable Diseases,2011,19(3):311-313. |
| |
| Authors: | Huang Jin-bo |
| |
| Institution: | Huang Jin-bo.Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College,Tianjin 300030,China |
| |
| Abstract: | The effect,such as complete remission,very good partial remission,progression-free survival and overall survival,of autologous stem cell transplantation are superior to traditional chemotherapy,which now has become the first choice for patients suffering from multiple myeloma who are under 65 years old.Thalidomide,lenalidomide and bortezomib plus dexamethasone are the new therapeutic regimen,and the traditional chemotherapy now is replaced by them.With the help of them,the effect of transplantation can be r... |
| |
| Keywords: | Multiple myeloma Transplantation of autologous stem cell Thalidomide Lenalidomide Bortezomib |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
